A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Latest Information Update: 05 Nov 2024
At a glance
- Drugs CRD 4730 (Primary)
- Indications Polymorphic catecholergic ventricular tachycardia
- Focus Adverse reactions
- Acronyms CPVT
- Sponsors Cardurion Pharmaceuticals
- 30 Oct 2024 New trial record